Hereditary hemochromatosis causes your body to absorb too much iron from food, with no natural way to get rid of the excess. Over years to decades, that iron builds up in the liver, heart, pancreas, and joints, and can eventually cause serious organ damage. It's caused primarily by mutations in the HFE gene — most commonly a variant called C282Y — and it is, genetically speaking, remarkably common in people of Northern European ancestry. That combination — common mutation, potentially serious disease, and a genuinely simple treatment — makes it one of the more interesting cases in consumer genomics.
Common Genotype, Uncommon Disease — and a Real Scientific Debate
Here's the part that surprises people: having two copies of C282Y (the genotype most associated with hemochromatosis) is common — as high as 1 in 200 to 1 in 250 in some Northern European and Irish populations. But actually developing clinically significant iron overload disease is considerably less common than the genotype itself, and exactly how much less common is a real, ongoing debate in the medical literature.
Some large population screening studies have found that only a small percentage of C282Y homozygotes — in some estimates under 5%, in others closer to 1% — ever develop the classic clinical disease (liver damage, diabetes, joint disease, and skin bronzing together). Other major cohort studies using biochemical markers of iron overload rather than full clinical disease as the yardstick have found a much higher figure — iron overload evidence in roughly a quarter of male carriers and lower in female carriers by middle age, rising further with age. The honest summary: nearly everyone with two copies of C282Y will show at least some biochemical sign of excess iron at some point, but only a minority ever progress to the kind of serious organ damage the disease is named for. Diet, alcohol intake, and other genetic and environmental factors appear to influence who progresses and who doesn't, and researchers haven't fully pinned down why.
| Measure | Approx. figure |
|---|---|
| C282Y homozygote frequency (Northern European/Celtic) | ~1 in 200–250 |
| Biochemical iron overload among homozygotes (varies by study/age/sex) | ~25–80% |
| Progression to serious clinical disease (liver damage, diabetes, etc.) | Debated — estimates range from under 5% to substantially higher |
Why It's Still Worth Knowing — Because It's Treatable
This is what makes hemochromatosis different from most genetic risk information: if you know early, the standard treatment is genuinely simple — regular therapeutic phlebotomy, essentially donating blood on a schedule, to keep iron levels down before damage accumulates. There's no specialized drug regimen, no complex ongoing therapy. Caught before organ damage sets in, people with hemochromatosis who manage their iron levels typically have a normal life expectancy. Caught late, after cirrhosis or heart damage has already occurred, the outlook is considerably worse and some of that damage isn't reversible.
That's the real argument for knowing your HFE status even though most carriers won't develop severe disease: the downside of not knowing (silent organ damage building for decades) is disproportionate to the upside of knowing (a simple, low-cost, low-risk management plan). It's a genuinely rare case in genetics where "found out early" changes the outcome this dramatically and this cheaply.
The C282Y genotype is common; severe clinical disease is much less common, and researchers still debate exactly how much less. But because the treatment — routine blood donation — is so simple and effective when started early, hemochromatosis is one of the strongest arguments for knowing your genetic status well before symptoms would ever prompt a doctor to test for it.
Should You Get Tested?
If you have a family history of hemochromatosis, unexplained fatigue, joint pain, liver enzyme abnormalities, or early-onset diabetes with no other clear cause, talk to your doctor about an iron panel (transferrin saturation and ferritin) alongside HFE genetic testing. Outside of a specific clinical trigger, HFE status is one of many actionable findings captured in comprehensive genome sequencing — and unlike a lot of genetic information, this is one where your doctor can actually act on a positive result with a low-cost, low-risk intervention.
Iron Overload Risk Is Hiding in Plain Sight — In Your Genome
Dante Labs' whole genome sequencing flags HFE and other clinically actionable variants alongside your carrier and ancestry results — one test, results you own for life. Use code GENOME for 10% off.
Get Sequenced with Dante Labs → 10% off with code GENOMECurious how a gene with such a common genotype but such variable real-world impact gets classified in the first place? Our explainer on variants of uncertain significance covers how labs handle genetic findings where the science isn't fully settled. And for the bigger picture on inherited disease risk, see our guide to genome testing and cancer risk.